US Capital Global Engaged by Med-X, Inc. as Strategic Advisor for $10MM Capital Formation


Global private financial group headquartered in San Francisco engaged by Los Angeles-based green technology manufacturer as strategic advisor.

SAN FRANCISCO, OCTOBER 2020 – US Capital Global has been retained by Med-X, Inc. (“Med-X”) as its strategic advisor for a $10 million capital formation. Med-X intends to use the additional financing to expand three of its natural products divisions, Nature-Cide, Thermal-Aid, and Malibu Brands, which are positioned for international distribution, as well as to further position the company to potentially go public and eventually be listed on a U.S. stock exchange.

Headquartered in Los Angeles, CA, Med-X is an innovator in developing all-natural, eco-friendly alternatives to products containing poisonous chemicals and harmful pharmaceuticals, often used in pest control, pain management, and agriculture. Med-X sells its products through leading international pest control distributors and applicators, as well as directly to American homes through partnerships with major retail and healthcare distributors.

Headquartered in San Francisco, US Capital Global is a full-service private financial group with an established track record in investment banking, asset management, and capital formation services. The firm provides sophisticated debt, equity, and investment products to lower middle market companies and investors. All securities are offered by the group through its FINRA-member, SEC-registered broker-dealer affiliate, US Capital Global Securities LLC.

Med-X CEO, Dr. David Toomey, states: “Over the last three years, the Nature-Cide and Thermal-Aid divisions of Med-X have continued to grow at a strong pace, now making it necessary to access large-scale capital to sustain inventory growth needs, pursue targeted acquisitions, and advance and expand the company’s international footprint. By securing more expansive financing, we are establishing the foundations for Med-X to potentially go public and be listed on a national stock exchange, thereby pursuing our goal of expanding Med-X into a global player with strong international market reach.”

“We are very excited to begin working with Dr. Toomey and his experienced team at Med-X,” said Jeffrey Sweeney, Chairman and CEO at US Capital Global. “The distribution relationships of Med-X’s product divisions are one of the key drivers for Med-X’s revenue growth, and these strong partnerships have emerged out of the tremendous need for innovative green solutions across multiple verticals. We look forward to supporting Med-X’s continued growth as the company’s strategic advisor for this $10 million capital formation.”

About Med-X, Inc.

Med-X is a leader in green technology manufacturing dedicated to providing consumers and communities with real solutions for living a healthy lifestyle without negatively impacting the environment. The company has developed a range of all-natural, plant-based brands, which include its Nature-Cide, Thermal-Aid, Home Spa, and Malibu Brands. Med-X has also entered the emerging Cannabis sector through such commercial activities as compound extraction of the identified hemp and cannabidiol (CBD) compounds. This is in response to rising consumer demand.

About US Capital Global

Established in 1998, US Capital Global leverages the latest FinTech and RegTech innovation to provide sophisticated debt, equity, and investment products to lower middle market companies and investors. The US Capital Global group manages direct investment funds and provides wealth management and capital raise services through its affiliates, including US Capital Global Investment Management LLC, US Capital Global Wealth Management LLC, and its FINRA-member, SEC-registered broker-dealer, US Capital Global Securities LLC. The group collaborates closely with its peers in professional banking and investment advisory. www.uscapglobal.com182010PR

To learn more about US Capital Global, email Jeffrey Sweeney, Chairman and CEO, at or call +1 415-889-1010.

Download a PDF of this Press Release

Sign up to our weekly newsletter

Click here

Contact our Media department

Click here